Act Now: Protect Your Investments in Treace Medical Concepts Before June 10 Deadline

The recent securities class action lawsuit against Treace Medical Concepts, Inc. (NASDAQ: TMCI) has exposed a critical inflection point for investors who held the company's stock during its alleged period of misconduct. With a

central to the case, the litigation underscores the importance of investor vigilance and strategic legal action in safeguarding financial interests. As the June 10, 2025, deadline for lead plaintiff submission approaches, investors must act decisively to preserve their recovery rights—or risk losing the opportunity to hold Treace Medical accountable for alleged fraud.

The Case Against Treace Medical: A Pattern of Misstatements

The lawsuit, McCluney v. Treace Medical Concepts, Inc., alleges that Treace Medical and its executives misled investors about the viability of its flagship product, the Lapiplasty 3D Bunion Correction System. Key claims include:
1. Downplaying Competition: The company allegedly concealed how competing minimally invasive osteotomy procedures and “knockoff” products eroded demand for Lapiplasty.
2. Revenue Decline and Strategic Shifts: Despite falling revenue, Treace Medical accelerated plans to develop its own MIS osteotomy system—a material fact omitted from public disclosures.
3. Stock Price Collapse: On May 7, 2024, the truth emerged. When Treace Medical disclosed its weakened financials, its stock plummeted nearly 63% in a single day ().

This abrupt decline reflects the depth of the alleged deception. Investors who purchased TMCI securities between May 8, 2023, and May 7, 2024, may have suffered significant losses due to the company's failure to disclose critical risks.

Why the June 10 Deadline Matters

The June 10, 2025, deadline is a pivotal moment for affected investors. Those who submit requests to become lead plaintiff can shape the litigation's direction and amplify its impact. Even those not seeking leadership roles should act:
- Preserve Recovery Rights: Without joining the class action, investors forfeit eligibility for any potential settlement or judgment.
- No Financial Risk: The case operates on a contingency fee basis, meaning plaintiffs pay nothing upfront. Legal fees are deducted only if the case succeeds.

The Role of Rosen Law Firm: Experience and Accountability

The Rosen Law Firm, a leader in securities litigation, is prominent in this case. Its track record includes:
- Top-Ranked Firm: Ranked #1 in securities class action settlements by ISS Securities Class Action Services in 2017.
- Substantial Recoveries: Secured over $438 million for investors in 2019, with a history of landmark victories.
- Proven Strategy: Founding partner Laurence Rosen's expertise ensures a rigorous approach to exposing corporate misconduct.

While other firms like Robbins Geller (with $2.5 billion in recoveries in 2024) and Levi & Korsinsky are also involved, Rosen's focus on shareholder advocacy positions it as a key ally for investors seeking accountability.

Strategic Litigation as a Shield Against Financial Losses

This case exemplifies how strategic litigation can mitigate investor harm. By holding companies accountable for misleading statements, lawsuits like McCluney force transparency and deter future misconduct. For TMCI investors, the stakes are clear:
- Recover Losses: The lawsuit aims to compensate those who relied on Treace Medical's false assurances.
- Prevent Future Fraud: A successful outcome could set a precedent for companies to prioritize honest disclosures over short-term gains.

Call to Action: Act Before Time Runs Out

Investors holding TMCI securities during the Class Period must act by June 10, 2025, to:
1. Join the Class Action: Visit
Rosen Law Firm's case portal, call toll-free at 866-767-3653, or email case@rosenlegal.com to submit a claim.
2. Consider Lead Plaintiff Status: Those with losses exceeding $100,000 can seek leadership to drive the case forward.

The clock is ticking. With Treace Medical's stock still reeling from the fallout of its admitted missteps, this is a rare opportunity to reclaim value lost to corporate deception.

Final Note: Don't Let Inaction Cost You

Investor protection is not passive—it demands proactive steps. By engaging with qualified legal counsel and acting before the June 10 deadline, affected investors can turn the tables on corporate wrongdoing and secure a measure of justice. The path forward is clear: act now, or risk losing the chance to recover what was taken.

For further details or to discuss your case, contact Rosen Law Firm at Laurence Rosen or Phillip Kim directly via their provided contact information. The fight for accountability begins with you.